New Zealand patients’ understanding of brand substitution and opinions on copayment options for choice of medicine brand
Charon Lessing A C , Toni Ashton A and Peter Davis A BA Health Systems Section, School of Population Health, University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand.
B Centre of Methods and Policy Application in the Social Sciences (COMPASS), Faculty of Arts, University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand.
C Corresponding author. Email: c.lessing@auckland.ac.nz
Australian Health Review 40(3) 345-350 https://doi.org/10.1071/AH15004
Submitted: 12 January 2015 Accepted: 30 July 2015 Published: 14 September 2015
Abstract
Objective The aim of the present study was to better understand the views and experiences of New Zealand patients on switching between brands of prescription medicines and on alternative funding options for the provision of medicines, including an increase in copayments.
Methods A self-administered questionnaire was offered to selected patients through participating community pharmacies. Pharmacies were stratified according to level of deprivation of the community served before random selection and invitation for involvement in the study. Patient understanding of and rationale for brand substitution was assessed. Preference for different copayment options was elicited, together with demographic and other explanatory information.
Results In all, 194 patient-completed questionnaires were returned. Some gaps in patient knowledge and understanding of brand changes were evident. Most respondents indicated a preference for the existing subsidy arrangements with little desire expressed for alternatives. Around half were willing to contribute towards paying for a choice of brand other than the subsidised brand; however, the maximum contribution nominated was disproportionately lower than real cost differences between originator brand and generics.
Conclusion The findings of the present study suggest that although most patients have experienced brand changes without any problems occurring, a lack of knowledge about substitution does persist. There may be some additional gain in ensuring New Zealanders are aware of the full cost of their medicines at the point of dispensing to reinforce the benefits of the Pharmaceutical Management Agency (PHARMAC) purchasing model.
What is known about the topic? Generic reference pricing is used as a mechanism to make savings to pharmaceutical budgets; however, reticence to the use of generic medicines persists.
What does this paper add? Most New Zealand patients experience brand changes without any problems occurring; however, a lack of knowledge about substitution does persist. The dollar value patients indicate they would contribute for brand choice is lower than the true cost difference between brands.
What are the implications for practitioners? Opportunities exist for healthcare professionals to reinforce generic policies and there may be some additional gain in ensuring New Zealanders are aware of the full cost of their medicines at the point of dispensing.
References
[1] Organization for Economic Cooperation and Development (OECD). Achieving better value for money in health care. Paris: OECD; 2009.[2] Morgan S, Hanley G, McMahon M, Barer M. Influencing drug prices through formulary-based policies: lessons from New Zealand. Healthc Policy 2007; 3 e121–40.
| 19305747PubMed |
[3] Associate Minister of Health. Medicines New Zealand. Contributing to good health outcomes for all New Zealanders. Wellington: NZ Government; 2007.
[4] Pharmaceutical Management Agency (PHARMAC). Purchasing medicines. 2014; Available at: https://www.pharmac.health.nz/assets/purchasing-medicines-information-sheet.pdf [verified 11 August 2015].
[5] Simoens S. Generic and therapeutic substitution: ethics meets health economics. Int J Clin Pharm 2011; 33 469–470.
| Generic and therapeutic substitution: ethics meets health economics.Crossref | GoogleScholarGoogle Scholar | 21431935PubMed |
[6] PHARMAC. New Zealand Pharmaceutical Schedule. Wellington: NZ Government; 2014.
[7] Olsson E, Kalvemark Sporrong S. Pharmacists’ experiences and attitudes regarding generic drugs and generic substitution: two sides of the coin. Int J Pharm Pract 2012; 20 377–83.
| Pharmacists’ experiences and attitudes regarding generic drugs and generic substitution: two sides of the coin.Crossref | GoogleScholarGoogle Scholar | 23134096PubMed |
[8] Heikkilā R, Mantyselka P, Ahonen R. Price, familiarity, and availability determine the choice of drug: a population-based survey five years after generic substitution was introduced in Finland. BMC Clin Pharmacol 2011; 11 20
| Price, familiarity, and availability determine the choice of drug: a population-based survey five years after generic substitution was introduced in Finland.Crossref | GoogleScholarGoogle Scholar | 22171800PubMed |
[9] Shrank WH, Cox ER, Fischer MA, Mehta J, Choudhry NK. Patients’ perceptions of generic medications. Health Aff 2009; 28 546–56.
| Patients’ perceptions of generic medications.Crossref | GoogleScholarGoogle Scholar |
[10] Shrank WH, Liberman JN, Fischer MA, Girdish C, Brennan TA, Choudhry NK. Physician perceptions about generic drugs. Ann Pharmacother 2011; 45 31–8.
| Physician perceptions about generic drugs.Crossref | GoogleScholarGoogle Scholar | 21205953PubMed |
[11] Gill LH. How do customers and pharmacists experience generic substitution? Int J Pharm Healthc Mark 2010; 4 375–95.
| How do customers and pharmacists experience generic substitution?Crossref | GoogleScholarGoogle Scholar |
[12] Rathe J, Larsen P, Andersen M, Paulsen M, Jarbol D, Thomsen J, Soendergaard J. Associations between generic substitution and patients’ attitudes, beliefs and experiences. Eur J Clin Pharmacol 2013; 69 1827–36.
| Associations between generic substitution and patients’ attitudes, beliefs and experiences.Crossref | GoogleScholarGoogle Scholar | 23765409PubMed |
[13] Pechlivanoglou P, van der Veen WJ, Bos JH, Postma MJ. Analyzing generic and branded substitution patterns in The Netherlands using prescription data. BMC Health Serv Res 2011; 11 89
| Analyzing generic and branded substitution patterns in The Netherlands using prescription data.Crossref | GoogleScholarGoogle Scholar | 21524312PubMed |
[14] Ping CC, March G, Clark A, Gilbert A, Hassali M, Bahari M. A web-based survey on Australian community pharmacists perceptions and practices of generic substitution. J Gene Med 2010; 7 342–53.
| A web-based survey on Australian community pharmacists perceptions and practices of generic substitution.Crossref | GoogleScholarGoogle Scholar |
[15] Decollogny A, Eggli Y, Halfon P, Lufkin TM. Determinants of generic drug substitution in Switzerland. BMC Health Serv Res 2011; 11: 17
| Determinants of generic drug substitution in Switzerland.Crossref | GoogleScholarGoogle Scholar |
[16] Frisk P, Rydberg T, Carlsten A, Ekedahl A. Patients’ experiences with generic substitution: a Swedish pharmacy survey. J Pharm Health Serv Res 2011; 2 9–15.
| Patients’ experiences with generic substitution: a Swedish pharmacy survey.Crossref | GoogleScholarGoogle Scholar |
[17] Granlund D. Are private physicians more likely to veto generic substitution of prescribed pharmaceuticals? Soc Sci Med 2009; 69 1643–50.
| Are private physicians more likely to veto generic substitution of prescribed pharmaceuticals?Crossref | GoogleScholarGoogle Scholar | 19815322PubMed |
[18] Mott DC. Exploring generic drug use behavior - The role of prescribers and pharmacists in the opportunity for generic drug use and generic substitution. Med Care 2002; 40 662–74.
| Exploring generic drug use behavior - The role of prescribers and pharmacists in the opportunity for generic drug use and generic substitution.Crossref | GoogleScholarGoogle Scholar |
[19] Denoth A, Pinget C, Wasserfallen J-B. Citizens’ preferences for brand name drugs for treating acute and chronic conditions: a pilot study. Appl Health Econ Health Policy 2011; 9 81–7.
| Citizens’ preferences for brand name drugs for treating acute and chronic conditions: a pilot study.Crossref | GoogleScholarGoogle Scholar | 21332252PubMed |
[20] Barnieh L, Clement F, Harris A, Blom M, Donaldson C, Klarenbach S, Husereau D, Lorenzetti D, Manns B. A systematic review of cost-sharing strategies used within publicly-funded drug plans in member countries of the Organisation for Economic Co-operation and Develpment. PLoS One 2014; 9 e90434
| A systematic review of cost-sharing strategies used within publicly-funded drug plans in member countries of the Organisation for Economic Co-operation and Develpment.Crossref | GoogleScholarGoogle Scholar | 24618721PubMed |
[21] Morgan S, Boothe K. Prescription drug subsidies in Australia and New Zealand. Aust Prescr 2010; 33 2–4.
[22] Sinnott S, Buckley C, O’Riordan D, Bradley C, Whelton H. The effect of copayments for prescriptions on adherence to medicines in publically insured populations; a systematic review and meta-analysis. PLoS One 2013; 8 e64914
| The effect of copayments for prescriptions on adherence to medicines in publically insured populations; a systematic review and meta-analysis.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3sXpsVKrsbw%3D&md5=0117e44f85711b1ee57c24ec0cbf2830CAS | 23724105PubMed |
[23] Jatrana SC. Ethnic differences in access to prescription medication because of cost in New Zealand. J Epidemiol Community Health 2011; 65 454–60.
| Ethnic differences in access to prescription medication because of cost in New Zealand.Crossref | GoogleScholarGoogle Scholar |
[24] Kemp A, Roughead E, Preen D, Glover J, Semmens J. Determinants of self-reported medicine underuse due to cost: a comparison of seven countries. J Health Serv Res Policy 2010; 15 106–14.
| Determinants of self-reported medicine underuse due to cost: a comparison of seven countries.Crossref | GoogleScholarGoogle Scholar | 20203082PubMed |
[25] Salmond C, Crampton P. Development of New Zealand’s deprivation index (NZDep) and its uptake as a national policy tool. Canadian Public Health Association 2012; 103 S7–S11.
[26] Babar Z, Grover P, Stewart J. Evaluating pharmacists’ views, knowledge, and perception regarding generic medicines in New Zealand. Res Social Adm Pharm 2011; 7 294–305.
| 21272551PubMed |
[27] Babar Z, Stewart J, Reddy S. An evaluation of consumers’ knowledge, perceptions and attitudes regarding generic medicines in Auckland. Pharm World Sci 2010; 32 440–448.
| 20559730PubMed |
[28] Statistics New Zealand. 2013 Census: profile and summary reports. 2014; Available at: http://www.stats.govt.nz/ [verified 4 February 2015].
[29] Beecroft G. Generic drug policy in Australia: a community pharmacy perspective. Aust New Zealand Health Policy 2007; 4 e1
[30] Löfgren H. Reshaping Australian drug policy: the dilemmas of generic medicines policy. Aust New Zealand Health Policy 2007; 4 11
| Reshaping Australian drug policy: the dilemmas of generic medicines policy.Crossref | GoogleScholarGoogle Scholar | 17543116PubMed |
[31] Mansfield SJ. Generic drug prices and policy in Australia: room for improvement? A comparative analysis with England. Aust Health Rev 2014; 38 6–15.
| Generic drug prices and policy in Australia: room for improvement? A comparative analysis with England.Crossref | GoogleScholarGoogle Scholar | 24480618PubMed |
[32] Organization For Economic Cooperation and Development (OECD). Health at a glance 2013: OECD indicators. Paris: OECD Publishing; 2013.
